Suven Life Sciences Ltd share price advanced by 5.64% to Rs 327.8 after the company's net profit jumped 179.85% to Rs 127.61 crore, while revenue from operations increased sharply by 134.87% to Rs 3.57 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Research, Analytics & Technology industry group stocks on BSE stood at Rs 41117.62 crore, retreating 10.12%. It has improved by 4.92% over last one week and crept higher by 5.03% in last one month while the market capitalization of Suven Life Sciences Ltd has marginally improved by 9.41% and 56.69% in the same period respectively. Profit before tax (PBT) of Suven Life Sciences Ltd stood at Rs 127.61 crore in Q2 FY26, surging by 147.69% year-on-year, and expanding by 179.85% quarter-on-quarter. EBITDA came in at Rs 140 crore, rallying 172.68% YoY and jumping 143.85% sequentially. Total expenses jumped by 157.20% to Rs 138.22 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 7.28 crore, witnessing a strong rise of 24.87% YoY. For the TTM ended FY26, revenue from operations tick up 6.76% to Rs 7.11 crore, while net profit soared by 71.91% to Rs 276.34 crore, compared to previous TTM. EBITDA plunged by 17789% to Rs 298.44 crore, and PBT witnessed a strong rise of 71.91% to Rs 276.34 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 301.79 crore in FY26, as against Rs 154.1 crore in FY25. Suven Life Sciences Ltd rallied 22.11% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.
